News

Filter

1 to 9 of 14 results

Hospira launches first biosimilar MAb Inflectra (infliximab) in major European markets

Hospira launches first biosimilar MAb Inflectra (infliximab) in major European markets

16-02-2015

US injectable generics and biosimilars major Hospira says it has launched the first biosimilar monoclonal…

Anti-Arthritics/RheumaticsBiosimilarsCellTrionEuropeGenericsHospiraInflammatory diseasesInflectraJohnson & JohnsonMarkets & MarketingMerck & CoRemicadeRemsima

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

21-01-2015

South Korea’s Samsung Bioepis says that the Marketing Authorization Application for its Enbrel (etanercept)…

AmgenAnti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEnbrelEuropePfizerRegulationSamsung Bioepis

Celgene’s oral Otezla approved by EC for psoriasis and psoriatic arthritis

Celgene’s oral Otezla approved by EC for psoriasis and psoriatic arthritis

18-01-2015

US biotech firm Celgene’s European subsidiary has received marketing authorization from the European…

Anti-Arthritics/RheumaticsBiotechnologyCelgene CorpDermatologicalsEuropeOtezlaRegulation

Astellas Xtandi approved in Europe for new indication; Janssen deal update

03-12-2014

Japanese pharma major Astellas Pharma has received European Commission approval for a variation to amend…

Anti-Arthritics/RheumaticsASP015KAstellas PharmaEuropeJanssen BiotechJohnson & JohnsonLicensingMedivationOncologyPharmaceuticalRegulationXtandi

EMA responds to Ombudsman questioning of AbbVie trial redactions

13-11-2014

The European Medicines Agency says it has taken note of the European Ombudsman’s recent remarks on…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulationResearch

Biotherapies could save millions of euros when treating auto-immune diseases

Biotherapies could save millions of euros when treating auto-immune diseases

08-10-2014

Health care providers could save millions of euros if biotherapies were used in the treatment of Crohn’s…

Anti-Arthritics/RheumaticsBiotechnologyEuropeFinancialHealthcareResearchTheradiag

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

Premium-price biologicals and novel therapies will drive psoriatic arthritis market growth

10-09-2014

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in…

AbbVieAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyEli LillyEuropeHumiraJapanMarkets & MarketingNovartisOtezlaStelaraUSAXeljanz

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top